Niagen Bioscience Inc

Total Valuation

Niagen Bioscience Inc carries a market capitalization of 252.47M, placing it among publicly traded companies globally. Its enterprise value stands at 187.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Niagen Bioscience Inc currently has 78.91M shares outstanding.

Valuation Ratios

Niagen Bioscience Inc trades at a trailing price-to-earnings ratio of 15.86. The price-to-sales ratio is 1.96, and the price-to-book ratio stands at 3.05.

Enterprise Valuation

On an enterprise value basis, Niagen Bioscience Inc trades at an EV/EBITDA multiple of 18.23 and an EV/FCF ratio of 30.09. The EV/Sales ratio of 1.45 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.74 provides insight into valuation relative to core operating earnings.

Financial Position

Niagen Bioscience Inc maintains a current ratio of 6.50, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Niagen Bioscience Inc posts a return on equity of 21.80 and a return on invested capital of 10.64.

Taxes

Over the trailing twelve months, Niagen Bioscience Inc has paid 1.04M in income taxes, reflecting an effective tax rate of 6.09.

Stock Price Statistics

Niagen Bioscience Inc's stock has declined approximately -65.98712% over the past 52 weeks. The 50-day moving average sits at 3.26, while the 200-day moving average is 4.68.

Income Statement

Over the trailing twelve months, Niagen Bioscience Inc generated 129.08M in revenue and converted that into 15.99M in net income, yielding earnings per share of 0.19. EBITDA reached 10.28M, while operating income came in at 8.62M.

Balance Sheet

Niagen Bioscience Inc holds 66.74M in cash and equivalents against 2.33M in total debt, resulting in a net debt position of -66.74M. Total book value stands at 82.53M, with working capital of 82.74M providing operational flexibility.

Cash Flow

Niagen Bioscience Inc produced 5.95M in operating cash flow over the past twelve months. After subtracting -275,000.00 in capital expenditures, free cash flow totaled 5.67M - equivalent to 0.07 per share.

Margins

Niagen Bioscience Inc operates with a gross margin of 64.24, reflecting its pricing power and cost economics. The operating margin of 6.67 and net profit margin of 12.39 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Niagen Bioscience Inc's most recent stock split took place on April 13, 2016 with a 3:1 split ratio.

Scores

Niagen Bioscience Inc posts an Altman Z-Score of 6.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.